BR112022021828A2 - Imunoterapia de citocina - Google Patents

Imunoterapia de citocina

Info

Publication number
BR112022021828A2
BR112022021828A2 BR112022021828A BR112022021828A BR112022021828A2 BR 112022021828 A2 BR112022021828 A2 BR 112022021828A2 BR 112022021828 A BR112022021828 A BR 112022021828A BR 112022021828 A BR112022021828 A BR 112022021828A BR 112022021828 A2 BR112022021828 A2 BR 112022021828A2
Authority
BR
Brazil
Prior art keywords
cytokine
immunotherapy
cytokine immunotherapy
polypeptide
cancer
Prior art date
Application number
BR112022021828A
Other languages
English (en)
Inventor
Akahata Wataru
F Smith Jonathan
Original Assignee
Vlp Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlp Therapeutics Inc filed Critical Vlp Therapeutics Inc
Publication of BR112022021828A2 publication Critical patent/BR112022021828A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

IMUNOTERAPIA DE CITOCINA. A presente invenção refere-se a um novo vetor de replicon de alfavírus imunologicamente ativo, que compreende um polinucleotídeo que codifica proteínas não estruturais de alfavírus nsp1-4 e polipeptídeo(s) / proteína(s) de uma citocina, o qual é útil para o tratamento de câncer e/ou doença inflamatória.
BR112022021828A 2020-04-30 2021-04-28 Imunoterapia de citocina BR112022021828A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017993P 2020-04-30 2020-04-30
PCT/JP2021/017078 WO2021221127A1 (en) 2020-04-30 2021-04-28 Cytokine immunotherapy

Publications (1)

Publication Number Publication Date
BR112022021828A2 true BR112022021828A2 (pt) 2023-01-17

Family

ID=78292585

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021828A BR112022021828A2 (pt) 2020-04-30 2021-04-28 Imunoterapia de citocina

Country Status (13)

Country Link
US (1) US20210340567A1 (pt)
EP (1) EP4143323A1 (pt)
JP (1) JP2023524055A (pt)
KR (1) KR20230005883A (pt)
CN (1) CN115552009A (pt)
AR (1) AR121961A1 (pt)
AU (1) AU2021264216A1 (pt)
BR (1) BR112022021828A2 (pt)
CA (1) CA3174651A1 (pt)
IL (1) IL297564A (pt)
MX (1) MX2022013638A (pt)
TW (1) TW202206448A (pt)
WO (1) WO2021221127A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086619A2 (en) * 2022-10-19 2024-04-25 Kalivir Immunotherapeutics, Inc. Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2099485T3 (en) * 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
WO2014170493A2 (en) * 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
US20170291934A1 (en) * 2014-09-22 2017-10-12 Charles C. Reed Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
CN110267978A (zh) * 2016-10-07 2019-09-20 得克萨斯大学体系董事会 用于治疗癌症的表达膜锚定的il-12的t细胞
WO2018213731A1 (en) * 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
BR112020012190A8 (pt) * 2017-12-20 2023-04-11 Vlp Therapeutics Llc Partícula de replicon de alfavírus

Also Published As

Publication number Publication date
TW202206448A (zh) 2022-02-16
MX2022013638A (es) 2023-01-24
AU2021264216A1 (en) 2022-11-10
CN115552009A (zh) 2022-12-30
EP4143323A1 (en) 2023-03-08
US20210340567A1 (en) 2021-11-04
KR20230005883A (ko) 2023-01-10
JP2023524055A (ja) 2023-06-08
IL297564A (en) 2022-12-01
AR121961A1 (es) 2022-07-27
WO2021221127A1 (en) 2021-11-04
CA3174651A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
EA201990229A1 (ru) Новый ботулинический нейротоксин и его производные
EA201891589A1 (ru) Условно активные гетеродимерные полипептиды и способы их применения
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
BR112019004770A2 (pt) anticorpos do vírus antidengue, polipeptídeos contendo regiões fc variantes, e métodos de uso
AR110567A1 (es) Conjugados específicos de anticuerpo-principio activo (adcs) con inhibidores de ksp (proteína del hueso de la quinecina)
MX2020007049A (es) Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus.
BR112022008092A2 (pt) Métodos de preparação de uma amostra enriquecida para sequenciamento polipeptídico
BR112022021828A2 (pt) Imunoterapia de citocina
EA202190999A1 (ru) Композиции на основе полипептидов, стабилизированных с помощью дисульфидной связи, и способы применения
BR112021023957A2 (pt) Peptídeos
BR112017001463A2 (pt) célula hospedeira melhorada para produzir proteínas
BR112022021604A2 (pt) Composições e métodos para tratamento de proteinopatias associadas à tdp-43
EA202290001A1 (ru) Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута
AR119271A1 (es) Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada
BR112022004497A2 (pt) Administração intranasal de escetamina
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
UY37752A (es) Proteínas de unión al antígeno anti-jagged1
BR112022020444A2 (pt) Composições e métodos para o tratamento de distúrbios de agregação de proteínas
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
BR112019004270A2 (pt) proteína livre de fenilalanina para o tratamento de pku
BR112022017718A2 (pt) Polipeptídeos de ulinastatina
BR112021018124A2 (pt) Linhagem celular compreendendo marcador de seleção e usos do mesmo para produção de proteína
BR112021023473A2 (pt) Vetores de terapia genética para osteopetrose maligna infantil
BR112017005573A2 (pt) enzima solubilizada e usos da mesma